Cargando…

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children

Tuberculosis (TB) is a major public health problem, with nearly 10 million new cases and millions of deaths each year. Around 10% of these cases are in children, but only a fraction receive proper diagnosis and treatment. The spread of drug-resistant (DR) strain of TB has made it difficult to contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Hanzhao, Zhou, Xintong, Zhuang, Zengfang, Li, Lianju, Bi, Jing, Mi, Kaixia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293792/ https://www.ncbi.nlm.nih.gov/pubmed/37384221 http://dx.doi.org/10.3389/fcimb.2023.1183597

Ejemplares similares

Trends and challenges of multi-drug resistance in childhood tuberculosis
por: Zhuang, Zengfang, et al.
Publicado: (2023)

Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in Mycobacterium tuberculosis
por: Guo, Qinglong, et al.
Publicado: (2022)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

1884. Clinical Outcomes Among Patients with Drug-Resistant Tuberculosis Receiving Bedaquiline or Delamanid Containing Regimens
por: Kempker, Russell R, et al.
Publicado: (2019)

Adverse Drug Reaction Monitoring in Multidrug-Resistant Tuberculosis Patients Receiving Bedaquiline and Delamanid-Based Regimen
por: Paikray, Elisha, et al.
Publicado: (2022)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid
por: Nieto Ramirez, Luisa Maria, et al.
Publicado: (2020)

In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates
por: Degiacomi, Giulia, et al.
Publicado: (2020)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

Editorial: Drug-resistant Mycobacterium tuberculosis
por: Boshoff, Helena I. M., et al.
Publicado: (2023)

Drug Resistance Characteristics of Mycobacterium tuberculosis Isolates From Patients With Tuberculosis to 12 Antituberculous Drugs in China
por: Wu, Xiaocui, et al.
Publicado: (2019)

Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs( )
por: Huerga, Helena, et al.
Publicado: (2022)

Effects of second-line anti-tuberculosis drugs on the intestinal microbiota of patients with rifampicin-resistant tuberculosis
por: Wu, Chunli, et al.
Publicado: (2023)

Transcriptional regulation and drug resistance in Mycobacterium tuberculosis
por: Miotto, Paolo, et al.
Publicado: (2022)

The evolving biology of Mycobacterium tuberculosis drug resistance
por: Jones, Richard M., et al.
Publicado: (2022)

Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan
por: Wu, Sheng-Han, et al.
Publicado: (2021)

The role of delamanid in the treatment of drug-resistant tuberculosis
por: Lewis, Joseph M, et al.
Publicado: (2015)

How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery
por: Bhagwat, Amala, et al.
Publicado: (2022)

Unraveling the mechanisms of intrinsic drug resistance in Mycobacterium tuberculosis
por: Poulton, Nicholas C., et al.
Publicado: (2022)

Evolution of Mycobacterium tuberculosis drug resistance in the genomic era
por: Nimmo, Camus, et al.
Publicado: (2022)

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
por: Yang, Jeong Seong, et al.
Publicado: (2018)

Whole Genome and Transcriptome Sequencing of Two Multi-Drug Resistant Mycobacterium tuberculosis Strains to Facilitate Illustrating Their Virulence in vivo
por: Tang, Jun, et al.
Publicado: (2020)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
por: Hu, Minhui, et al.
Publicado: (2016)

Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis
por: Rancoita, Paola M. V., et al.
Publicado: (2018)

Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management
por: Liebenberg, Dale, et al.
Publicado: (2022)

Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in Mycobacterium tuberculosis
por: Eoh, Hyungjin, et al.
Publicado: (2022)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Editorial: Tuberculosis Drug Discovery & Development: Drug Targets, Chemical Matter, and Approaches
por: Singh, Vinayak
Publicado: (2021)

Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
Publicado: (2019)

Drug-resistant strains of Mycobacterium tuberculosis: cell envelope profiles and interactions with the host
por: Schami, Alyssa, et al.
Publicado: (2023)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Understanding the contribution of metabolism to Mycobacterium tuberculosis drug tolerance
por: Samuels, Amanda N., et al.
Publicado: (2022)

Uncovering interactions between mycobacterial respiratory complexes to target drug-resistant Mycobacterium tuberculosis
por: McNeil, Matthew B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ocs73a9lrcb0vb9lo6qb651h3n